NYSE: GKOS ยท Medical Devices
Glaukos (GKOS) fair value and price range
As of 14 Nov 2026, Faircurve's model values Glaukos (GKOS) at $228.07 a share. The stock last closed at $244.88, which puts the model's fair value 6.9% below the price. The inputs behind this valuation are under review, so no verdict is shown.
- The stock trades on multiples far outside what a peer comparison can handle, so the fair value is a rough guide only.
Revalued . Price is the close of 16 Nov 2026. Glaukos Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $208.30 to $228.07 (+9.5%). The multiple the model anchors on moved, lifting the fair value: most of the move.
What the model makes of itThe price of $244.88 is 6.9% above it. The inputs behind this valuation are under review, so no verdict is shown.
What's nextNext report on 16 Feb 2027. Options prices imply a move of about 15% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give GKOS?
The calibrated range for GKOS over 63 trading days is $205.78 to $293.97. It sits around the last close, and its width comes from the volatility that GKOS's own options imply (53% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $176.44 to $293.00. In 40% of the simulations the fair value came out above the price the model ran on.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does GKOS report earnings, and how has the stock reacted?
Glaukos's next earnings report is scheduled for 16 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 12.3% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. GKOS's 30 day implied volatility works out to about 15.2% over one month.
How GKOS moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 12.1%.
| Report date | Two session move |
|---|---|
| 4 Nov 2026 | -5.6% |
| 28 Oct 2026 | +33.8% |
| 29 Jul 2026 | +11.4% |
| 29 Apr 2026 | +20.1% |
| 17 Feb 2026 | +10.5% |
| 29 Oct 2025 | +12.9% |
| 30 Jul 2025 | -8.2% |
| 20 Feb 2025 | -21.6% |
How does GKOS score on business quality?
Glaukos's overall quality score is 54 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 5 | -9.4%ROIC | 7.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 96 | 32.3%Revenue growth, trailing | 11.6% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 69 | 0.0%Net buybacks / market value | 1.3% |
| Balance sheetNet debt to EBITDA and interest coverage. | 50 | 0.49xNet debt / EBITDA | 1.07x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 17 | 5.6 ptsEBITDA margin downside volatility, 5y | 2.7 pts |
How does GKOS compare with similar companies?
The companies in medical devices closest to Glaukos in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| PEN Penumbra, Inc. | $320.62 | $296.43 | -7.5% | Fairly valued |
| ALGN Align Technology, Inc. | $165.98 | $200.67 | +20.9% | Undervalued |
| ZBH Zimmer Biomet Holdings, Inc. | $101.41 | $120.99 | +19.3% | Undervalued |
| PODD Insulet Corp. | $145.29 | $158.48 | +9.1% | Fairly valued |
| BIO Bio-Rad Laboratories, Inc. | $360.26 | $340.60 | -5.5% | Fairly valued |
| GMED Globus Medical, Inc. | $70.50 | $76.21 | +8.1% | Fairly valued |
| BRKR Bruker Corporation | $60.62 | $64.27 | +6.0% | Fairly valued |
| DXCM DexCom, Inc. | $81.61 | $73.84 | -9.5% | Fairly valued |
What the comparable companies' multiples alone would give for GKOS, the peer-implied price, is $29.55 a share on this run. The fair value weighs that against the company's own multiple.
Glaukos at a glance
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases.
- Market value
- $14.5B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $976M
- Consensus revenue growth, next fiscal year
- +53.8%
- Analysts with estimates
- 8
- Beta to the US market
- 1.01
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Glaukos on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for GKOS was $208.30. As of 14 Nov 2026 it is $228.07, a change of +9.5%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Glaukos's valuation
Is Glaukos stock undervalued or overvalued?
Faircurve's model puts GKOS's fair value at $228.07 a share against a last close of $244.88, as of 14 Nov 2026. The inputs behind this valuation are under review, so no verdict is shown.
What is GKOS's fair value?
$228.07 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $176.44 to $293.00.
What price range does the model give GKOS?
$205.78 to $293.97 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Glaukos report earnings next?
The next report is scheduled for 16 Feb 2027. Companies can move their dates.
How much has GKOS moved on past earnings reports?
Across its last 8 reports the median two session move was 12.1%, ignoring direction. The largest was +33.8% around the report of 28 Oct 2026.
How confident is the model in this valuation?
The model's evidence grade for GKOS is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.